Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL-N)

NCT03635632 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT03635632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03635632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL-N)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 23, 2019
Completion date
May 16, 2038
Enrollment
94 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

phyllodes breast tumor, refractory neuroblastoma, relapsed ewing sarcoma, relapsed neuroblastoma, relapsed osteosarcoma, relapsed rhabdomyosarcoma, uveal melanoma